Abstract: The aim of this study was to investigate the effect of polymorphisms in cytochrome P450 (CYP) 2D6, CYP3A4 and CYP3A5 enzymes and in P-glycoprotein (P-gp) on the pharmacokinetics and safety of aripiprazole and, its active metabolite, dehydro-aripiprazole, in 148 healthy volunteers from six bioequivalence trials receiving a single oral dose of aripiprazole. The plasma concentrations of both analytes were measured by LC-MS/MS. CYP2D6 (*3,*4,*5,*6,*7,*9 and copy number variations), CYP3A4 (*20 and *22), CYP3A5*3 and C3435T, C1236T and G2677T/A in ABCB1 gene were determined. As the number of active CYP2D6 alleles decreased, AUC 0Àt , C max and t 1/2 of aripiprazole were higher and clearance of aripiprazole, AUC 0Àt of dehydro-aripiprazole and ratio dehydro-aripiprazole/aripiprazole were lower. AUC 0Àt of aripiprazole of poor metabolizer (PM) subjects was increased by 50% compared to extensive metabolizers (EM), and AUC 0Àt of dehydro-aripiprazole was decreased by 33%. ABCB1 1236TT subjects had a lower clearance of aripiprazole (p = 0.023) and AUC 0Àt (p = 0.039) and C max of dehydroaripiprazole (p = 0.036) compared to C/C. CYP3A5*3/*3 subjects had a 10% lower ratio dehydro-aripiprazole/aripiprazole than *1/*3 (p = 0.019). Adverse drug reactions (ADRs) had a directly proportional relationship with AUC 0Àt of aripiprazole (p = 0.001), especially nausea/vomiting, which were more common in women (p = 0.005). Women and CYP3A5*1/*1 subjects showed more often dizziness (p = 0.034; p = 0.009). Pharmacokinetics of aripiprazole is affected by CYP2D6 phenotype but also by sex and C1236T (ABCB1 gene), while dehydro-aripiprazole pharmacokinetics is affected by CYP2D6 and C1236T. The ratio dehydro-aripiprazole/aripiprazole was influenced by CYP2D6 phenotype and CYP3A5*3. Concentrations of aripiprazole, sex, CYP3A5*3 and CYP2D6 were involved in the development of ADRs.
Aripiprazole is an atypical antipsychotic indicated for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder [1] . Its mechanism of action differs from the rest of atypical antipsychotics; it acts as a partial agonist at the dopamine D 2 , dopamine D 3 and serotonin 5-HT 1A receptors and as an antagonist at the serotonin 5-HT 2A receptors [2] [3] [4] . Furthermore, it exhibits a moderate affinity for a1 adrenergic and histamine H 1 receptors [5, 6] .
Aripiprazole is extensively metabolized in the liver by the cytochrome P450 (CYP) 2D6 and CYP3A4 by dehydrogenation, hydroxylation and N-dealkylation [7] . Its active metabolite, dehydro-aripiprazole, represents around 40% of the parent drug levels in plasma [8] . Dehydro-aripiprazole seems to have similar pharmacological properties to aripiprazole; some authors have even reported that it could be more powerful than the parent drug [9] .
CYP2D6 is a highly polymorphic gene with more than 150 allelic variants [10] . According to CYP2D6 genotype, subjects can be classified in four phenotypes [11] : poor metabolizers (PMs), intermediate metabolizers (IM), extensive metabolizers (EM) or ultra-rapid metabolizers (UM). It has been described that PMs are exposed to higher concentrations of aripiprazole and lower concentrations of dehydro-aripiprazole, being its exposure to the total drug moieties 60% higher than EMs [1] . For these reasons, a dose adjustment could be necessary for PMs [12] .
The other enzyme involved in the metabolism of aripiprazole is CYP3A4. The CYP3A4*20 polymorphism produces a non-functional protein that could lead to higher levels of drugs in subjects carrying CYP3A4*20 alleles [13] . In spite of this, currently there are no studies focusing on the influence of CYP3A4*20 on the pharmacokinetics of aripiprazole. Recently, a new allelic variant named CYP3A4*22 has been described [14] , and this variant produces an enzyme with a reduced activity that can affect the metabolism of antipsychotic drugs such as quetiapine [15] .
Due to the similar substrate specificity between CYP3A4 and CYP3A5, some drugs metabolized by CYP3A4 are also metabolized by CYP3A5 [16] and their pharmacokinetics could be affected by CYP3A5 polymorphisms [17] . CYP3A5*3, the most frequent non-functional variant of Author for correspondence: Francisco Abad Santos, Clinical Pharmacology Department, Hospital Universitario de la Princesa, Diego de Le on 62, 28006 Madrid, Spain (e-mail francisco.abad@salud.madrid.org).
CYP3A5, produces a non-functional protein. Subjects with the CYP3A5*3/*3 genotype do not express CYP3A5 [18, 19] , so it is expected that these subjects will have higher concentrations of aripiprazole.
Both aripiprazole and dehydro-aripiprazole are substrates of P-glycoprotein (P-gp) [20] . Gene ABCB1 (ATP-binding cassette subfamily B 1) encodes P-gp that is involved in drug absorption, distribution and elimination [21, 22] . C3435T SNP (rs1045642) in ABCB1 is related to level of expression and function of ABCB1, and thereby drug plasma concentrations. However, results have not been very clarifying to date, while some authors affirm that subjects with T/T genotype could have less duodenal expression of ABCB1 that could lead to higher levels of drugs [23] ; other authors claim the opposite [24, 25] . Another two SNPs, C1236T (rs1128503) and G2677T/A (rs2032582), have been reported to influence the response to several antipsychotics like clozapine, haloperidol and risperidone [26] .
We have investigated the effect of polymorphisms in the metabolizing enzymes (CYP2D6, CYP3A4 and CYP3A5) and in the drug transporter (ABCB1) on the pharmacokinetics of aripiprazole and dehydro-aripiprazole in a population of healthy volunteers receiving a single oral dose of aripiprazole. In addition, we have analysed the effect of these polymorphisms on adverse drug reactions (ADRs).
Methods
Study population. The study population comprised 148 healthy volunteers (85 men and 63 women) who were enrolled in six bioequivalence clinical trials performed at the Clinical Trial Unit of Hospital Universitario de la Princesa (Madrid, Spain). These trials were approved by the Research Ethics Committee of the Hospital, duly authorized by the Spanish Drug Agency and conducted following the guidelines of Good Clinical Practice. All the volunteers gave written informed consent for both clinical trial and pharmacogenetic study. The subjects were free to withdraw from the study at any time.
The inclusion criteria were healthy volunteers aged from 18 to 55 years and free from any organic or psychic conditions. Exclusion criteria were subjects who had received prescribed pharmacological treatment in the last 15 days or any kind of medication in the 48 hr prior to receiving the study medication, body mass index outside the 18.5-30.0 kg/m 2 range, smoker, history of sensitivity to any drug, pregnant women or lactose intolerance.
Study design and procedures. All the clinical trials were phase I, single oral dose, randomized, open-label, crossover, two-period, twosequence, single-centre studies with blind determination of the plasma concentrations of aripiprazole for the responsible analyst. In three of the trials, the volunteers received aripiprazole 10-mg tablets, while in the other three, the volunteers received aripiprazole 10-mg orodispersible tablets. In the first period, each volunteer received a single dose of one formulation of aripiprazole (test or reference). After a washout period of 28 days, each volunteer received the same dose of the other formulation in the second period. The volunteers fasted from 10 hr before to 5 hr after drug administration. In all the studies, the reference formulation was Abilify â (Otsuka Pharmaceutical Laboratories Europe, London, UK). As there were no pharmacokinetic differences among all the formulations (test and reference showed bioequivalence, and orodispersible tablets showed a similar profile to tablets), we used all data for the investigation of the influence of sex and polymorphisms on the pharmacokinetics of aripiprazole and its metabolite. Twenty blood samples (before taking the drug and until 72 hr after dosing) were collected in 6-mL sterile EDTA-K2 tubes. Samples were centrifuged at 3500 rpm (1900 9 g) for 10 min., and then, plasma was collected and stored at À20°C.
Drug assay. Aripiprazole concentrations were measured in an accredited external laboratory by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The lower limit of quantification (LLOQ) was 0.5 ng/mL. The method involved solid-phase extraction procedure with strong cation-exchange and reversed-phase 10-mg plates. Chromatographic separations were performed on a reversed-phase column (Zorbax SB-C18, 4.6 9 50 mm, 3.5 lm, from Agilent Technologies, Santa Clara, CA, USA). The mobile phase was ammonium formate 1 mM, 0.1% formic acid prepared in Milli-Q, Merck Millipore (Billerica, Massachusetts, USA) water: methanol (42:58 v/v). The chromatographic separation was isocratically performed at room temperature at a flow rate of 1.00 mL/min. Also, dehydro-aripiprazole was determined in 103 volunteers (58 men and 45 women) by LC-MS/MS. For this purpose in our laboratory, we have developed and validated a method for monitoring dehydro-aripiprazole in human plasma using aripiprazole-d8 as the internal standard (IS) [27] . The method was validated according to the recommendations published online by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The analytes and IS were extracted from 200 lL of human plasma by solid-phase extraction using Oasis PRiME HLB 96-well lElution Plate, 3 mg sorbent per well (Waters, Madrid, Spain). Separations were carried out at 25°C in an ACE C18-PFP column (4.6 mm 9 100 mm and 3-lm particle size (SYMTA, Madrid, Spain) protected by a 0.2-lm online filter. The mobile phase consisted of a combination of 0.2% formic acid and 0.3% ammonia in Milli-Q water pH 4.0 (solution A) and acetonitrile (solution B) (65:35, v/v). The chromatogram was run under gradient conditions at a flow rate of 0.6 mL/min. Run-time was 5 min. followed by a re-equilibration time of 3 min., to give a total run-time of 8 min. The volume injected into the chromatographic system was 5 lL. The analyte was detected using the multiple reaction monitoring in the positive ionization mode. The LLOQ was 0.35 ng/mL, and the linearity of the method was established in the concentration range 0.35-100 ng/mL.
Pharmacokinetic
analysis. Pharmacokinetic parameters were estimated by non-compartmental analysis using WinNonlin Professional, version 2.0. (Pharsight Corporation Cary, NC, USA). C max and T max were obtained directly from raw data. AUC 0-∞ was calculated as the sum of AUC 0Àt and the residual area (C t divided by k e , with C t as the last measured concentration and k e as the apparent terminal elimination rate, which was estimated by log-linear regression from the terminal portion of the log-transformed concentration-time plots). T 1/2 was calculated by dividing 0.693 by k e . The total drug clearance adjusted for bioavailability (CL/F) was calculated by dividing the dose by the AUC 0-∞ and adjusted for weight. Volume of distribution adjusted for bioavailability (V/F) was calculated by dividing the CL/F by k e . AUC 0Àt and C max were adjusted for dose and weight and logarithmically transformed for statistical analysis. For dehydro-aripiprazole only AUC 0Àt (truncated to 72 hr) and C max were calculated because there were not enough sampling times in the elimination phase. The ratio of AUC 0Àt of dehydro-aripiprazole/ aripiprazole was also calculated.
Genotyping. DNA was extracted from 1 mL of peripheral blood samples using an automatic DNA extractor (MagNa Pure â System, Roche Applied Science, Indianapolis, Indiana, USA) and quantified spectrophotometrically in a NanoDrop â ND-1000 Spectrophotometer (Wilmington, Delaware, USA). The following polymorphisms were analysed: CYP3A4*20, CYP3A4*22, CYP3A5*3, CYP2D6 (*3, *4, *5, *6, *7, *9, copy number variations, *1 9 N and *4 9 N) and three SNPs on ABCB1 (C3435T, C1236T and G2677T/A). All the polymorphisms (except CYP2D6 *1 9 N, *4 9 N) were genotyped using real-time polymerase chain reaction (PCR). CYP2D6*3, CYP2D6*4 and CYP2D6*5 were determined using a LightCycler instrument version 2.0 (Roche Diagnostics, Mannheim, Germany), while the others were performed in a StepOne TM instrument (Applied Biosystems, Foster City, CA, USA). The CYP3A4*20 polymorphism was genotyped using KASPar SNP Genotyping System (LGC Genomics, Herts, UK). The Sequence Detection System ABI PRISM 7900HT (Applied Biosystems, Darmstadt, Germany) was used for fluorescence detection and allele assignment. All CYP3A4*20 carriers were confirmed by Sanger sequencing run on an ABI PRISM 3700 DNA Analyzer capillary sequencer (Applied Biosystems, Foster City, CA, USA).
CYP2D6 copy number assays. Copy number variations in the CYP2D6 gene were determined using a commercial assay, TaqMan Copy Number Assay (Applied Biosystems, Foster City, CA, USA), which detects a specific sequence on exon 9 (Assay ID: Hs00010001_cn). All samples were run in quadruplicate in a StepOne Plus PCR instrument (Applied Biosystems, Foster City, CA, USA). A known copy number of CYP2D6 sample from Coriell Institute was used as positive control (three copies, Coriell ID: NA17221). The assay was performed with an endogenous control, RNaseP TaqMan Copy Number Reference Assay (Assay ID: 4403326; Applied Biosystems, Foster City, CA, USA). To calculate the exact copy number of samples, we used CopyCaller Software (Applied Biosystems, Foster City, CA, USA); this software uses the comparative DDCT method for this purpose [28] . For those subjects who were heterozygous and had three or more copies of the gene, allele-specific copy number variations were identified using Droplet Digital PCR technology following the manufacturer's instructions (Bio-Rad, Pleasanton, CA, USA).
Safety. Throughout the study, the volunteers were inquired about any experienced adverse events (AE). Also, those AEs spontaneously notified by the volunteer were recorded. Karch and Lasagna criteria were used to determine causality [29] and only those which were definite, probable or possible were considered as ADRs. According to the drug label [1] , ADRs were classified using 'System Organ Class' allocation as general, cardiovascular, gastrointestinal, genitourinary, neurological, psychiatric and respiratory.
Statistical analysis. Statistical analysis was performed using the SPSS 23.0 software (SPSS Inc., Chicago, Ill, USA); p-values <0.05 were considered statistically significant.
Hardy-Weinberg equilibrium was estimated for all analysed variants, using a Fisher exact test based on the De Finetti program [30] . Differences in the genotypic frequencies of variants according to gender were determined using a corrected Pearson v 2 -test. To study the influence of genotypes on pharmacokinetics, we used ANOVA (except for polymorphisms with only two categories where we used t-test). Tukey's post hoc test was used to compare means between groups. The corrected Pearson v 2 -test was applied to compare the relationship between ADRs and genotypes.
Pharmacokinetic data were logarithmically transformed, except T max and ratio of AUC 0Àt of dehydro-aripiprazole/aripiprazole, in accordance with EMA guideline on the investigation of bioequivalence [31] .
G2677T/A genotypes were divided into three groups depending on the activity of the alleles: 'A/A+A/T', 'C/A+C/T' and 'C/C'. Also, we only found a carrier of the allele *20 so we regrouped him with the carriers of the allele *22.
As there were three SNPs of the ABCB1 and these variables are partially linked, models were run to determine the relationship among them as well as their possible second-order interactions with each dependent.
Multiple linear regression models were used to study factors related to all the pharmacokinetic dependent variables. Variable selection procedures enter and stepwise with probabilities of entry and exit of 0.05 and 0.1 were used. Models for each dependent with standardized (b) and unstandardized (B) regression coefficients are shown in "Results" section. Goodness of fit is shown by multivariate coefficient of determination R 2 corrected and global adjust by ANOVA F statistic and significance.
Logistic regression models with dichotomous outcome were used to study factors related to the following ADRs: any ADR, dizziness, headache and nausea/vomiting. Variable selection procedures enter and stepwise forward (likelihood ratio) with probabilities of entry and exit of 0.05 and 0.1 were used. Significance of coefficients and odds ratio (OR) is shown in "Results" section. In both models, assumptions were checked.
Results

Demographic characteristics.
Our study population comprised 148 healthy volunteers (85 men and 63 women) who were enrolled in six bioequivalence clinical trials. Average age was similar between men and women (25.4 AE 6.7 years versus 27.8 AE 8.8 years, respectively). However, men were taller than women (1.76 AE 0.06 m versus 1.64 AE 0.06 m; p < 0.001) and weighed more (76.2 AE 9.0 kg versus 61.4 AE 8.3 kg; p < 0.001). All the subjects were Caucasian, except 11 latin, one mixed and one Black.
Genotypic frequencies.
All genetic variants analysed were in Hardy-Weinberg equilibrium (p ≥ 0.05, Pearson v 2 test), except CYP2D6*7 because no subject expressed this allele. All subjects were genotyped for all the variants, except for CYP3A4*20 (n = 144 subjects). Genotype frequencies are shown in table 1. These frequencies did not differ between men and women.
Pharmacokinetic analysis. Table 2 shows mean and standard deviation of the pharmacokinetic parameters of aripiprazole and dehydro-aripiprazole of the total amount of volunteers and according to sex.
Women had higher values of AUC 0Àt , C max , T 1/2 and V/F of aripiprazole compared to men, as table 2 shows, but there were no differences in CL/F. After adjusting AUC 0Àt and C max for dose/weight, they still remained statistically significant (p = 0.021 and p = 0.020), but both parameters were higher in men than in women. In contrast, for dehydro-aripiprazole, there were no differences except in unadjusted C max . However, the total active moiety (sum of aripiprazole and dehydro-aripiprazole) was higher in women for AUC 0Àt (2143.0 AE 415.1 versus 1942.4 AE 414.0 in men; p = 0.014) and C max (61.0 AE 11.7 versus 53.4 AE 10.1 in men; p = 0.001). After adjusting both parameters for dose/weight, they still remained statistically significant (p = 0.011 and p = 0.016) but both of them were higher in men than in women. No differences between men and women in the ratio dehydro-aripiprazole/aripiprazole (p = 0.466) were found.
Influence of genetic polymorphisms on pharmacokinetics. The pharmacokinetic parameters of aripiprazole (table 3) , dehydro-aripiprazole and total active moiety (table 4) according to different genotypes of studied polymorphisms are reflected as mean and standard deviation.
Influence of CYP2D6 on pharmacokinetics of aripiprazole. CYP2D6 phenotype was associated with changes in the pharmacokinetic parameters of aripiprazole. As the number of active alleles decreased, AUC 0Àt (p < 0.001) and T 1/2 (p < 0.001) were higher and CL/F was lower (p < 0.001). C max was also influenced by CYP2D6 phenotype (p = 0.045), but these differences were not statistically significant after adjusting for weight (p = 0.078).
For dehydro-aripiprazole, as the number of active CYP2D6 alleles decreased, a significant decrease in AUC 0Àt and C max was observed (p < 0.001 in both cases).
Furthermore, the ratio of AUC 0Àt dehydro-aripiprazole/aripiprazole was also influenced by CYP2D6 (p < 0.001). Also, CYP2D6 phenotype had an impact on the AUC 0Àt of the total active moiety (p = 0.018), but after adjusting for dose/weight, these differences were not statistically significant (p = 0.106).
Influence of CYP3A4 on pharmacokinetics of aripiprazole. Neither pharmacokinetic parameters of aripiprazole nor dehydro-aripiprazole were influenced by CYP3A4 genotype (tables 3 and 4). However, a trend was observed as the only subject who was a carrier of the allele *20 had a higher AUC 0Àt of aripiprazole, a lower AUC 0Àt of dehydro-aripiprazole and a very low ratio. This subject was EM for CYP2D6 but its parameters were similar to IM CYP2D6 subjects.
Influence of CYP3A5 on pharmacokinetics of aripiprazole. Although there were no statistically significant differences on pharmacokinetic parameters of aripiprazole or dehydro-aripiprazole between the CYP3A5 polymorphisms (tables 3 and 4), we found an association between CYP3A5*3 and the ratio dehydro-aripiprazole/aripiprazole, as *1/*1 and *1/*3 subjects had higher values of this parameter when compared to *3/*3 (p = 0.019).
Influence of ABCB1 on pharmacokinetics of aripiprazole. None of the SNPs on this gene had a significant effect on neither the AUC 0Àt nor the C max of aripiprazole, but its clearance was influenced by C1236T (p = 0.023) and G2677T/A genotypes (p = 0.037), as C/C subjects had higher values of this parameter compared to T/T C1236T and A/A G2677T/A.
As shown in table 4, AUC 0Àt of the dehydro-aripiprazole was influenced by G2677T/A (p = 0.021) and C1236T polymorphisms (p = 0.039) and the same happened with the C max (p = 0.037 and p = 0.036, respectively), as subjects with C/C genotype had higher values of this two parameters when compared with the other categories. Also, the ratio dehydro-aripiprazole/aripiprazole was influenced by G2677T/A (p = 0.026) and C3435T (p = 0.050) polymorphisms.
After running the model to determine the relationship among the three above-mentioned SNPs, only the C1236T SNP was associated with the dependent variables, and there were no significant interactions with the other two SNPs on the same gene.
Pharmacokinetic multiple regression analysis. Multiple regression analysis (table 5) showed that all the pharmacokinetic parameters of the parent drug (except clearance) were influenced by sex and CYP2D6 phenotype. Clearance was affected by C1236T SNP on ABCB1 gene and CYP2D6 phenotype. Likewise, AUC 0Àt and C max of dehydro-aripiprazole were influenced by C1236T SNP and CYP2D6 phenotype. AUC 0Àt of the total active moiety was related to sex and CYP2D6 phenotype and C max was only influenced by sex. The ratio dehydro-aripiprazole/aripiprazole was influenced by CYP2D6 phenotype and CYP3A5 genotype.
Adverse drug reactions. During the development of these studies, 108 volunteers (73.0%) suffered at least one ADR. The most frequent ADRs were dizziness (38.5%), nausea/vomiting (30.4%), prolonged QTc (21.6%) and headache (19.6%). By group, the most frequent ADRs were neurological (52.0%) and gastrointestinal (31.8%).
Subjects who suffered at least one ADR had higher values of unadjusted AUC 0Àt (1695.9 AE 414.8 versus 1458.7 AE 318.3, 3 , p = 0.008) and C max (60.6 AE 9.5 versus 55.1 AE 11.9, p = 0.018) of the total active moiety. Also, we found an association between CYP2D6 phenotype and nausea/ vomiting (p = 0.014) being more frequent in PM (33.3%) and IM (44.3%) subjects compared to EM (20.8%) and UM (14.3%). An association between CYP3A5*3 and the development of dizziness was also found (60% of *1/*1 subjects, 20.6% of *1/*3 subjects and 43.1% of *3/*3 subjects; p = 0.028).
After performing a multiple logistic regression, the development of any ADR was only influenced by the AUC 0Àt of aripiprazole (p = 0.002; OR = 1.308 for every increase in 0.1 units of the Ln AUC 0Àt ). Headache was not influenced by sex or other factors (p = 0.065). The development of nausea/vomiting was still influenced by sex (p = 0.03; OR = 2.29) and AUC 0Àt of aripiprazole (p = 0.003; OR = 1.289 for every increase in 0.1 units of the Ln AUC 0Àt ) but it was not influenced by CYP2D6 phenotype anymore. Finally, CYP3A5*3 and sex had an effect on the development of dizziness as women and *1/*1 subjects (when compared to *1/*3) were more prone to suffer this ADR (p = 0.034, OR = 2.158; p = 0.009, OR = 0.281, respectively).
The development of any ADR and of nausea/vomiting was also influenced by the AUC 0Àt of the total active moiety, but as there were only 103 subjects for this variable and the statistical significance was better for the AUC 0Àt of aripiprazole, we chose the AUC 0Àt of the parent drug as independent variable for the logistic regression model. However, any ADR was related to dehydro-aripiprazole's pharmacokinetics.
Discussion
Sex influence on pharmacokinetics. The pharmacokinetic parameters obtained in our study are similar to those published in the literature [32, 33] and shown in the drug label [1] . AUC 0Àt , C max , T 1/2 and V/F were higher in women than in men. These results are consistent with information in the drug label [1] , which states that 'C max and AUC of aripiprazole are 30% to 40% higher in women than in men. These differences, however, are largely explained by differences in body-weight (25%) between men and women'. However, we found small differences (14% and 11% for unadjusted C max and AUC 0Àt , and 7% for both parameters after adjusting for dose/weight) that were statistically significant even after adjusting for dose/weight. AUC 0Àt and C max were lower in women, although there were no differences in CL/F. Influence of sex on drug pharmacokinetics is a quite well-known aspect. There are different factors involved in these differences, such as hormonal changes or body composition [34, 35] . Women present a higher V/F than men, due to their higher fat percentage [34] . As there were no differences in CL/F or ratio dehydro-aripiprazole/aripiprazole, the fact that adjusted AUC 0Àt and C max are lower in women than in men could be explained by the higher V/F in women. Nevertheless, the differences between men and women are small (around 10%) and less relevant than differences among CYP2D6 genotypes; so, they do not justify a different dose because of sex.
Influence of genetic polymorphisms on pharmacokinetics.
CYP2D6. Our study confirms the influence of CYP2D6 polymorphisms on the pharmacokinetics of aripiprazole and our results are in accordance with other authors [12, 19, 36, 37] . Currently, regulatory agencies as the FDA or the EMA are including pharmacogenetic information in drug labels. As the Abilify â FDA drug label [1] states, PMs have around an 80% increase in aripiprazole exposure and a 30% decrease in exposure to dehydro-aripiprazole compared to EM resulting in a 60% higher exposure to the total active moieties. In our study, in PM the AUC 0Àt of aripiprazole was increased by 50% compared to EM while AUC 0Àt of dehydro-aripiprazole was decreased by 33%. Regarding total active moieties, PMs were exposed to 31% greater concentrations than EM, results that are very similar to the showed by Hendset et al. 2007 [12] . According to these results, we agree suggesting a dose reduction similar to that of 50% in PM recommended by FDA [1] . Despite this evidence, the genotyping of CYP2D6 is not implemented in routine clinical practice yet and we consider that this study can help to educate physicians in the importance of genotyping patients in order to adjust dose and to prevent ADRs produced by high concentrations of drugs.
CYP3A4. In our study, CYP3A4*22 did not show a significant effect on the pharmacokinetic parameters of aripiprazole nor of dehydro-aripiprazole, as also reported by other studies carried out in patients [36, 38] . On the basis of these results, we conclude that although it seems CYP3A4 enzyme plays an important role on the metabolism of both aripiprazole and dehydro-aripiprazole [39] , its identified allelic variants like CYP3A4*22 are not able to predict variability in drug response to aripiprazole. However, we did not find any subject carrying two *22 alleles which could show a significant influence in the clearance of the drug. Further, we only identified one subject carrying one CYP3A4*20 allele who showed a very low dehydro-aripiprazole/aripiprazole ratio; these data should be confirmed in other studies.
CYP3A5. So far, little is known about the effect of CYP3A5*3 on aripiprazole metabolism. Currently, studies have reported no influence of CYP3A5*3 on pharmacokinetics of aripiprazole [19, 37, 40] . Interestingly, our results showed that the dehydro-aripiprazole/aripiprazole ratio is influenced by CYP3A5*3, with *3/*3 subjects having a lower metabolism, which is consistent with previous information of this allelic variant [18] . However, the influence of CYP3A5 on the pharmacokinetics of aripiprazole and dehydro-aripiprazole is much smaller than the CYP2D6, as *3/*3 have around a 10% reduced ratio compared to *1/*3 and PM have a 50% reduced ratio compared to EM.
ABCB1. We showed for the first time the influence of the C1236T SNP on the pharmacokinetics of aripiprazole. The lower clearance of aripiprazole in T/T subjects could be related to a lower activity of P-gp in these subjects [41] . The effect of this SNP on the clearance of several drugs, mainly chemotherapies such as docetaxel [42] and irinotecan [43] , has been previously described and these results are in agreement with ours, as T/T subjects had a lower clearance too. Also, T/ T subjects had lower AUC 0Àt and C max of the dehydroaripiprazole, a fact that might be caused by an induction effect of the P-gp on the responsible cytochromes on the transformation from aripiprazole to dehydro-aripiprazole (mainly CYP3A4). As previously reported [44] , T/T subjects for G2677T/A (linked to C1236T and C3435T) had a decrease in CYP3A4 induction by rifampicin. In our study, the low levels of dehydro-aripiprazole described in T/T subjects for C1236T could be explained by a possible decrease in CYP3A4 induction. The greater influence of this SNP on the levels of the dehydro-aripiprazole than on the levels of the parent drug could be due to a higher affinity of dehydroaripiprazole to P-gp [45] . Our negative findings regarding the other two SNPs (C3435T and G2677T/A) are in agreement with those reported in a population of Japanese adult patients [19] . However, a study performed recently in Caucasian paediatric patients showed an effect of both polymorphisms on the pharmacokinetics of aripiprazole as subjects with the 2677TT/3435TT genotype had lower aripiprazole concentrations [38] . Up to now, studies focusing on the role of these polymorphisms on the pharmacokinetics of different drugs have been discordant; consequently, further research is required before adjusting dose recommendations could be advised.
Adverse drug reactions.
In our study population, females and subjects with higher concentrations of aripiprazole showed more often nausea/vomiting. Influence of sex on ADRs has been reported in several studies [46, 47] ; the higher percentage of women suffering ADRs might be due to their higher exposure to drugs [48] . As previously published by our group [49] , there seems to be a clear relationship between concentrations of aripiprazole and the development of ADRs as reported in an extensive review [50] ; the higher percentage of ADRs (especially nausea/vomiting) in subjects with higher AUC 0Àt found in our study could be due to a higher blockage of dopamine receptors. Aripiprazole concentrations are more important than dehydro-aripiprazole concentrations to produce these side effects. Although CYP2D6 seemed to be associated with the development of nausea/vomiting, this relationship was only due to higher concentrations of aripiprazole in the subjects with slower CYP2D6 phenotype (PM and IM). Thus, CYP2D6 phenotype could be a good pharmacogenetic marker for predicting the risk of nausea/vomiting.
As CYP3A5 is also expressed in the brain [51] , higher frequencies of dizziness for *1/*1 subjects found in our study could be due to a significant role of this enzyme in the brain metabolism of aripiprazole which could possibly lead to a modified response to the drug, as previously shown with other psychotropic drugs like alprazolam [52] .
While both aripiprazole and aripiprazole + dehydro-aripiprazole concentrations were related to ADRs like nausea/vomiting, concentrations of aripiprazole would have a greater impact on the safety of this drug. In summary, concentrations of aripiprazole along with the sex were the main factors implied in the development of ADRs in the treatment with aripiprazole while genetic polymorphisms had a minor role.
Study limitations.
The main limitation of our study is the impossibility to evaluate the influence of the above-mentioned polymorphisms on the efficacy of the drug and the development of chronic ADRs (like extrapyramidal symptoms, weight gain or diabetes). Also, we consider that the time sampling was not long enough for an adequate evaluation of AUC and elimination of dehydro-aripiprazole and for subjects with long T 1/2 of aripiprazole like CYP2D6 PM subjects. Another limitation of our study is that aripiprazole and dehydro-aripiprazole were measured by two different analytical laboratories but as both laboratories use methods that have been validated according to the guidelines of regulatory agencies, we consider that it hardly has any impact on the results. On the other hand, our study enables us to evaluate the effect of genetic polymorphisms on the response to aripiprazole without the interference of confounding factors such as smoking, concomitant treatments and the characteristics of the psychiatric diseases. Moreover, the multiple regression analysis, allow us to evaluate the role of each polymorphism.
It is important to consider that these results must be interpreted with caution because pharmacokinetics and tolerability could be different in psychotic patients receiving long-term treatment. In addition, it would be desirable to increase the sample size in order to improve statistical power, mainly for some rare genotypes.
Conclusions
The pharmacokinetics of aripiprazole is affected mainly by CYP2D6 phenotype and to a lesser extent by sex and C1236T SNP in ABCB1 gene, while the pharmacokinetics of dehydro-aripiprazole solely is affected by CYP2D6 and C1236T SNP. Also, CYP3A5*3 (along with CYP2D6) has an impact on the ratio dehydro-aripiprazole/aripiprazole. The pharmacokinetics of aripiprazole and dehydro-aripiprazole is not affected by neither CYP3A4*22 nor C3435T and G2677T/A SNPs on ABCB1 gene. Also, the development of ADRs is mainly influenced by aripiprazole's concentrations and sex but also CYP3A5 and CYP2D6 polymorphisms had an effect on the safety of aripiprazole.
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